Abstract
The population on hemodialysis (HD) is vulnerable to several complications, such as uremic dyslipidemia, chronic inflammation and increased oxidative stress (OS), which negatively affect the time and quality of life for these patients. In recent decades, new therapies were introduced for the purposes of improving the morbidity and mortality in this group, however, without much success. Ba…